Most Recent
A judge overseeing a dispute over an employer's confidential information has urged litigants to remember their legal costs at an early stage of settlement negotiations, rather than leaving it to the court as the “default option”.
In submissions to the High Court, the applicant in a class action brought on behalf of Arrium shareholders against KMPG has attacked the Attorney-General’s argument that a contingency fee order is a neutral factor in assessing the accounting firm’s bid to move the case from Victoria.
A contradictor has argued against Monash IVF’s bid for orders allowing it to retain embryos as evidence in a class action, saying the Victorian Supreme Court has no power to make orders inconsistent with the company's statutory obligation to store embryos for a maximum of five years.
A former EY partner and ousted board member at National Tiles has lost his $1 million claim alleging the company breached implied terms in a contract by requiring him to sign a “draconian, unreasonable and unacceptable” share agreement.
Super Retail Group's former chief legal officer and company secretary has brought court proceedings to enforce what she claims was a settlement reached three days after her employment was terminated in May.
An appeals court has knocked back builder Hanssen’s attempt to dodge a decade-old dispute over repairs to one of its residential buildings on constitutional grounds, saying the Perth company's argument would precipitate an “extraordinary” result if accepted.
A judge has set aside a decision upholding misconduct findings against a former Australian National University PhD student, who was concerned the decision could affect his career prospects in the law.
Experts say the chaos of last month’s CrowdStrike outage is likely to spark a flurry of litigation both overseas and at home, including class actions, but lawyers bringing the claims will face significant hurdles.
A lawsuit against the Commonwealth by a former staffer who accused South Australian MP Rebekha Sharkie of bullying has been discontinued.
A law firm is investigating claims against the manufacturers of popular heartburn and acid reflux drugs, alleging they could be responsible for causing stomach cancers and kidney failure in approximately 100,000 people.